%0 Journal Article
%A Jecmenica Lukic, Milica
%A Respondek, Gesine
%A Kurz, Carolin
%A Compta, Yaroslau
%A Gelpi, Ellen
%A Ferguson, Leslie W
%A Rajput, Alex
%A Troakes, Claire
%A van Swieten, John C
%A Giese, Armin
%A Roeber, Sigrun
%A Herms, Jochen
%A Arzberger, Thomas
%A Höglinger, Günter
%A Giese, Armin
%A Troakes, Claire
%A Gelpi, Ellen
%A Respondek, Gesine
%A Höglinger, Günter U
%A van Swieten, John
%A Arzberger, Thomas
%A Compta, Yaroslau
%A Molina-Porcel, L.
%A Aldecoa, I.
%A Tolosa, E.
%A Martí, M. J.
%A Valldeoriola, F.
%A Pagonabarraga, J.
%A Calopa, M.
%A Bayès, A.
%A Hernandez, I.
%A Aguilar, M.
%A Genis, D.
%T Long-duration progressive supranuclear palsy: clinical course and pathological underpinnings.
%J Annals of neurology
%V 92
%N 4
%@ 0364-5134
%C Hoboken, NJ
%I Wiley-Blackwell
%M DZNE-2022-01385
%P 637-649
%D 2022
%X To identify the clinical characteristics of the subgroup of benign progressive supranuclear palsy with particularly long disease duration; to define neuropathological determinants underlying variability in disease duration in progressive supranuclear palsy.Clinical and pathological features were compared among 186 autopsy-confirmed cases with progressive supranuclear palsy with ≥10 years and shorter survival times.45 cases (24.2
%K Astrocytes: metabolism
%K Autopsy
%K Disease Progression
%K Humans
%K Neurons: metabolism
%K Supranuclear Palsy, Progressive: pathology
%K tau Proteins: metabolism
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:35872640
%R 10.1002/ana.26455
%U https://pub.dzne.de/record/164981